#Johnson & Johnson

All articles tagged with "Johnson & Johnson"

A surgical robot working on a patient. J&J has developed and submitted OTTAVA for FDA approval.

Johnson & Johnson Reports First Clinical Study Results for OTTAVA Surgical Robot

Johnson & Johnson says its investigational OTTAVA robotic surgical system met primary safety and performance endpoints in a 30-patient gastric-bypass study.

Key Takeaways

J&J says OTTAVA met primary endpoints in a 30-patient gastric-bypass study.
All procedures in the study were completed robotically without conversion.

DT Editorial Team·May 7, 2026·via therobotreport.com

J&J Pulls Back Two Lymphoma CAR-T Programs as the Treatment Market Shifts

Johnson & Johnson is discontinuing two CAR-T therapy programs for B-cell lymphoma, pointing to an increasingly crowded treatment landscape shaped by recent approvals in cell therapy and antibody-based drugs.

Key Takeaways

Johnson & Johnson is scrapping two CAR-T programs for B-cell lymphoma.
The company cites an evolving market for the decision.

DT Editorial Team·May 2, 2026·via endpoints.news

Biopharma’s Week in Focus: Peptide Policy, Pipeline Momentum, and the Start of Earnings Scrutiny

A sparse but telling weekly roundup from Endpoints News points to three pressures shaping biotech right now: regulation, clinical momentum, and investor scrutiny.

Key Takeaways

Endpoints News highlighted RevMed’s success, FDA peptide reclassification, and the start of Q1 earnings season.
The supplied text also mentions Johnson & Johnson’s confidence in navigating biosimilar competition.

DT Editorial Team·Apr 18, 2026·via endpoints.news